S100A8/A9‐High Macrophages Activate Intestinal Fibroblasts via mCCL6/hCCL15‐CCR1 Axis to Drive Intestinal Fibrosis in Crohn's Disease
Advanced Science · 2026
DOI: 10.1002/advs.76353 ↗At a glance
Journal article in Advanced Science, 2026. Written by Shu Wang and 12 co-authors. Institution: Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China. Major MEDLINE topics: Crohn Disease, Macrophages, Calgranulin B, Calgranulin A. 62 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, China Postdoctoral Science Foundation.
Abstract (original language)
Intestinal fibrosis presents a major clinical challenge in Crohn's disease (CD) due to the lack of effective pharmacological interventions. The underlying mechanisms of intestinal fibrosis remain largely elusive. Reanalysis of the single‐cell RNA‐seq data from full‐thickness CD tissue identifies a distinct profibrotic macrophage subset characterized by high S100A8 and S100A9 expression. CellChat analysis indicates strong communication between this S100A8/A9‐high (S100A8/A9 hi ) macrophage subset and fibroblasts. Adoptive transfer of S100A8/A9 hi macrophages exacerbate intestinal fibrosis in mice with chronic dextran sulfate sodium (DSS)‐induced colitis. Consequently, pharmacological inhibition of S100A8/A9 significantly ameliorates intestinal fibrosis in murine chronic colitis. Proteomic analysis further identifies murine CCL6 (mCCL6) as the key pro‐fibrotic mediator secreted by S100A8/A9 hi macrophages, which acts via CC chemokine receptor 1 (CCR1) to regulate fibroblasts. Antibody blockade of mCCL6 alleviates established intestinal fibrosis in a DSS‐induced colitis model. Mechanistically, S100A8/A9 hi macrophages drive mCCL6 production via STAT3 activation. Similarly, the human ortholog of CCL6, CCL15 (hCCL15), exerts pro‐fibrotic effects on fibroblasts via the CCR1 receptor. Our findings reveal that targeting S100A8/A9 hi macrophage may be a therapeutic strategy against intestinal fibrosis in CD.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China.
ORCID profiles: Chunhua Jiao, Hongjie Zhang
Funding
- National Natural Science Foundation of China
- China Postdoctoral Science Foundation
Cite
APA
Wang, S., Wang, J., Lin, J., Ye, Z., Zhou, G., Ma, J., Sun, J., Yu, J., Zhang, Y., Tang, N., Jiao, C., Zhao, X., & Zhang, H. (2026). S100A8/A9‐High Macrophages Activate Intestinal Fibroblasts via mCCL6/hCCL15‐CCR1 Axis to Drive Intestinal Fibrosis in Crohn's Disease. Advanced Science. https://doi.org/10.1002/advs.76353
Vancouver
Wang S, Wang J, Lin J, Ye Z, Zhou G, Ma J, et al. S100A8/A9‐High Macrophages Activate Intestinal Fibroblasts via mCCL6/hCCL15‐CCR1 Axis to Drive Intestinal Fibrosis in Crohn's Disease. Advanced Science. 2026. doi:10.1002/advs.76353
BibTeX
@article{Wang2026,
author = {Wang, Shu and Wang, Jiayun and Lin, Junjie and Ye, Ziping and Zhou, Geyujia and Ma, Jingjing and Sun, Junjian and Yu, Jiang and Zhang, Yingdi and Tang, Nana and Jiao, Chunhua and Zhao, Xiaojing and Zhang, Hongjie},
title = {S100A8/A9‐High Macrophages Activate Intestinal Fibroblasts via mCCL6/hCCL15‐CCR1 Axis to Drive Intestinal Fibrosis in Crohn's Disease},
journal = {Advanced Science},
year = {2026},
doi = {10.1002/advs.76353}
}
EUVIMED